The effects of SGLT2 inhibitors on atrial fibrillation recurrence and cardiac function after catheter ablation in patients with atrial fibrillation and heart failure: a retrospective cohort study and meta-analysis - Takeaways - MDSpire

The effects of SGLT2 inhibitors on atrial fibrillation recurrence and cardiac function after catheter ablation in patients with atrial fibrillation and heart failure: a retrospective cohort study and meta-analysis

  • By

  • Xueying Gao

  • Zhanxin Zhang

  • Kexin Chen

  • Yaqiong Jin

  • Fei Chen

  • Jie Zhang

  • Lu Geng

  • Keke Wang

  • Cunliang Gao

  • Li Wang

  • Jingchao Lu

  • May 1, 2026

  • 0 min

Share

  • 1

    SGLT2 inhibitors significantly reduce the recurrence of atrial fibrillation after catheter ablation in patients with heart failure.

  • 2

    The SGLT2i group showed a lower atrial arrhythmia recurrence rate (13.25%) compared to the non-SGLT2i group (25.88%).

  • 3

    SGLT2 inhibitors are associated with improved cardiac function, evidenced by reduced left atrial diameter and increased left ventricular ejection fraction.

  • 4

    A meta-analysis of 13 studies confirmed that SGLT2 inhibitors lower the risk of atrial arrhythmia recurrence post-ablation.

  • 5

    SGLT2 inhibitors are linked to decreased all-cause mortality and reduced heart failure occurrences in patients with atrial fibrillation.

Original Source(s)

The effects of SGLT2 inhibitors on atrial fibrillation recurrence and cardiac function after catheter ablation in patients with atrial fibrillation and heart failure: a retrospective cohort study and meta-analysis

  • by Xueying Gao, Zhanxin Zhang, Kexin Chen, Yaqiong Jin, Fei Chen, Jie Zhang, Lu Geng, Keke Wang, Cunliang Gao, Li Wang, Jingchao Lu

  • May 1, 2026

Related Content

5 Big Changes in Cardiac Surgery

Craig J. Baker, MD, chief of cardiac surgery for the Keck School of Medicine of USC, explains key developments reshaping the field.

  • by

  • January 15, 2026

  • 12 min
One Night's Sleep May Predict 130 Diseases

Foundation model trained on more than half a million hours of polysomnography data outperforms demographic baselines in forecasting mortality, dementia, and cardiovascular outcomes

GLP-1s: A Quiet Drop-Off in Seniors

For many seniors, breakthrough weight-loss drugs deliver real benefits — until insurance denials, side effects, or muscle loss force them to quit.